Literature DB >> 18780859

New response criteria proposed for immunotherapies.

Rabiya S Tuma.   

Abstract

Mesh:

Substances:

Year:  2008        PMID: 18780859     DOI: 10.1093/jnci/djn334

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  7 in total

1.  Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Authors:  Ben C Creelan; Scott Antonia; David Noyes; Terri B Hunter; George R Simon; Gerold Bepler; Charles C Williams; Tawee Tanvetyanon; Eric B Haura; Michael J Schell; Alberto Chiappori
Journal:  J Immunother       Date:  2013-10       Impact factor: 4.456

Review 2.  Targeting TGF-β Signaling for Therapeutic Gain.

Authors:  Rosemary J Akhurst
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-10-03       Impact factor: 10.005

Review 3.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506

Review 4.  Evaluation of tumor response to cytokine-induced killer cells therapy in malignant solid tumors.

Authors:  Xiao-Dong Li; Mei Ji; Xiao Zheng; Zhong-Hua Ning; Jun Wu; Binfeng Lu; Chang-Ping Wu; Jing-Ting Jiang
Journal:  J Transl Med       Date:  2014-08-12       Impact factor: 5.531

5.  Trastuzumab combined with doublet or single-agent chemotherapy as first-line therapy for HER2-positive metastatic breast cancer.

Authors:  Y F Yu; Y Wang; T P Fu; K Chen; J Q Liu; H R Yao
Journal:  Breast Cancer Res Treat       Date:  2017-11-29       Impact factor: 4.872

Review 6.  Response Evaluation of Chemotherapy for Lung Cancer.

Authors:  Ki-Eun Hwang; Hak-Ryul Kim
Journal:  Tuberc Respir Dis (Seoul)       Date:  2017-03-31

Review 7.  The Evaluation of Response to Immunotherapy in Metastatic Renal Cell Carcinoma: Open Challenges in the Clinical Practice.

Authors:  Alessandra Raimondi; Giovanni Randon; Pierangela Sepe; Melanie Claps; Elena Verzoni; Filippo de Braud; Giuseppe Procopio
Journal:  Int J Mol Sci       Date:  2019-08-30       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.